Sun J, et al. - Researchers evaluated the prognosis factors of signet-ring cell carcinoma (SRCC) and evaluated if the adjuvant therapy could supply benefit for SRCC with different regimens. Findings suggested a pessimistic prognosis of patients with colon SRCC, however, still the effective role of adjuvant therapy for OS was observed in stage III SRCC patients who received surgery. Similarly, benefit could be gained by the patients with stage IV SRCC from systemic therapy. As per results in stage III, an improvement in the overall survival (OS) could be achieved with 5-FU-based adjuvant chemotherapy for AC and SRCC patients, the OS could be further enhanced by adding oxaliplatin.